It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Safety is a key concern for investors. Learn which option, index funds or individual stocks, offers better security for your investments.
24,450 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Palantir's Alex Karp has reignited the AI debate, arguing that the market overstates near-term gains from frontier mo...
As Apple gears up for a major investor update, investors face a timing decision. This article provides a practical fr...
Figma reports Q4 2025 revenue of $303.8 million, up 40% year over year, pushing annual revenue over the $1 billion ma...
Cuba warns that an intensifying oil embargo is pushing its health system toward collapse, threatening everyday safety...
Snowflake’s stock dips after the company outlines a mixed outlook for 2026, signaling a slower path to profitability ...
Is Occidental Petroleum a smart move for your portfolio in 2026? This guide breaks down the debt story, cash flow, an...
A new government estimate links weekly economic losses from the Israel-Hamas/Iran front to alert levels, while Bitcoi...
A new jobs report shows US payrolls fell in February even as energy costs surged and stocks slid, challenging the ide...
Analysts warn that Nvidia's GTC event may not deliver the dramatic stock move some investors were banking on. The con...
Insider stock moves can be alarming, but they aren’t always a red flag. This guide explains how to read a fastly stoc...
Oil sits near $102 per barrel in mid-March 2026 as markets digest supply discipline, demand recovery, and policy move...